Entrectinib - Ignyta

Drug Profile

Entrectinib - Ignyta

Alternative Names: NMS-E628; RXDX-101

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Ignyta; Nerviano Medical Sciences
  • Class Antineoplastics; Benzamides; Indazoles; Piperazines; Pyrans; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Neuroblastoma
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 18 Oct 2017 Updated interim efficacy and adverse events data from the phase II STARTRK-2 trial in Non small cell lung cancer released by Ignyta
  • 17 Oct 2017 Entrectinib receives Priority Medicine (PRIME) status for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union
  • 18 Sep 2017 Ignyta initiates a phase I pharmacokinetics study in patients with Solid tumours in USA (NCT03330990)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top